Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Our objective is to examine “coverage, price, and reimbursement” (“CPR”) for multigene tests broadly and for cancer-related indications, specifically, why tests are covered/not covered by payers, how this is changing over time, and how CPR influences testing decisions and practices in clinic settings.
Prime PI is Kathryn A. Phillips, Ph.D., UCSF. Site PI is Su-Ying Liang, Ph.D.
National Institutes of Health - National Cancer Institute
Cancer Liquid Biopsy Monitoring Study
Investigators: Deepti Behl, MD, Mohammed Kashani-Sabet, M.D.
COVID-19 Impacts on Cancer Care Management, Patient Experience and Care Costs
Investigators: Cheryl Stults, Ph.D., Monique de Bruin, M.D., MPH, Su-Ying Liang, Ph.D.
Stupski Serious Illness Program Evaluation
Investigator: Sylvia Sudat, PhD
Impact of COVID-19 on Cancer Care Management
Investigators: Monique de Bruin, M.D., MPH, Su-Ying Liang, Ph.D.
Improving Cancer Care
Investigator: Su-Ying Liang, Ph.D.
Multilevel Study of Lung Cancer Screening Guidelines Implementation (MUST)
Investigator: Jiang Li, Ph.D., MPH
Implementing Universal Lynch Syndrome Screening Across Multiple Healthcare Systems: Identifying Strategies to Facilitate and Maintain Programs in Different Organizations Contexts
Investigators: External PI, Principal Investigator, Monique de Bruin, M.D., MPH, Su-Ying Liang, Ph.D.
Lung Cancer in Never Smokers: Incidence, Risk Factors and Molecular Characteristics in Asian American, Native Hawaiian, and Pacific Islander (AANHPI) Women
Investigators: Su-Ying Liang, Ph.D., External PI, Principal Investigator
Using Electronic Health Records to Understand Pathways of Breast Cancer Screening and Care
Breast Cancer Chemoprevention in Primary Care at Geisinger
Investigators: External PI, Principal Investigator, Xiaowei (Sherry) Yan, PhD, MS